Cargando…
Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
We recently read with interest the original research article entitled "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy". The abovementioned article is an observational retrospective cohort study, which could be...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403700/ https://www.ncbi.nlm.nih.gov/pubmed/36159549 http://dx.doi.org/10.12998/wjcc.v10.i23.8425 |
_version_ | 1784773437623894016 |
---|---|
author | Argyriou, Konstantinos Kotsakis, Athanasios |
author_facet | Argyriou, Konstantinos Kotsakis, Athanasios |
author_sort | Argyriou, Konstantinos |
collection | PubMed |
description | We recently read with interest the original research article entitled "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy". The abovementioned article is an observational retrospective cohort study, which could be of particular value for clinicians to understand how immunotherapy affects pre-existing enteral disease in inflammatory bowel disease patients. Although we appreciate the endeavor of Samuel Rubin et al, based on our in-depth analysis, we detected a potential shortcoming in this article; thus, we present our comments in this letter. If the authors contemplate these comments on their relevant research, we believe that their contribution would be considerable for future studies. |
format | Online Article Text |
id | pubmed-9403700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-94037002022-09-23 Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” Argyriou, Konstantinos Kotsakis, Athanasios World J Clin Cases Letter to the Editor We recently read with interest the original research article entitled "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy". The abovementioned article is an observational retrospective cohort study, which could be of particular value for clinicians to understand how immunotherapy affects pre-existing enteral disease in inflammatory bowel disease patients. Although we appreciate the endeavor of Samuel Rubin et al, based on our in-depth analysis, we detected a potential shortcoming in this article; thus, we present our comments in this letter. If the authors contemplate these comments on their relevant research, we believe that their contribution would be considerable for future studies. Baishideng Publishing Group Inc 2022-08-16 2022-08-16 /pmc/articles/PMC9403700/ /pubmed/36159549 http://dx.doi.org/10.12998/wjcc.v10.i23.8425 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Letter to the Editor Argyriou, Konstantinos Kotsakis, Athanasios Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” |
title | Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” |
title_full | Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” |
title_fullStr | Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” |
title_full_unstemmed | Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” |
title_short | Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” |
title_sort | comment on “disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy” |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403700/ https://www.ncbi.nlm.nih.gov/pubmed/36159549 http://dx.doi.org/10.12998/wjcc.v10.i23.8425 |
work_keys_str_mv | AT argyrioukonstantinos commentondiseaseexacerbationiscommonininflammatoryboweldiseasepatientstreatedwithimmunecheckpointinhibitorsformalignancy AT kotsakisathanasios commentondiseaseexacerbationiscommonininflammatoryboweldiseasepatientstreatedwithimmunecheckpointinhibitorsformalignancy |